JB Pharma Q4FY25 net profit Rises 15% on domestic, CDMO strength

JB Pharma

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

JB Chemicals & Pharmaceuticals (JB Pharma) on Wednesday reported a 15 percent year-on-year rise in net profit for the fourth quarter of FY25, driven by strong performance in its domestic formulations and contract development and manufacturing (CDMO) businesses. Net profit rose to ₹146 crore, while revenue grew 10 percent to ₹949 crore.

The Q4 EBITDA rose 15 percent YoY to ₹240 crore with an EBITDA margin at 25.3 percent.

The return on capital employed (ROCE)improved to 32 percent from 27 percent in FY24. The net cash stood at ₹689 crore as of March 31, 2025

For the full fiscal year, revenue rose 12 percent to ₹3,918 crore, and net profit climbed 19% to ₹660 crore. Operating EBITDA for FY25 crossed the ₹1,000 crore mark for the first time, reaching ₹1,087 crore with a margin of 27.7 percent.

“We have closed the financial year FY25 on a strong note, in line with our strategic intent and sustained execution in the market,” said Nikhil Chopra, CEO and Whole-time Director. “Our Domestic business continues to be one of the fastest growing in IPM. With 75% of India branded formulations sales in progressive, faster-growing segments, we are confident in sustained strong performance going forward.”

Domestic formulations revenue grew 11 percent YoY in Q4 to ₹519 crore and 20 percent for FY25 to ₹2,269 crore. Chronic therapies led the growth, with the Cilacar franchise crossing ₹785 crore in annual sales.

International business revenue rose 9 percent YoY in Q4 to ₹430 crore, with CDMO contributing ₹129 crore, up 18 percent. For FY25, international revenue grew 4 percent to ₹1,649 crore.

The CDMO business rebounded in the second half of FY25, contributing 27 percent of international revenue and closing several global projects expected to commercialize over the next 12–18 months.

"Together our Domestic and CDMO business now constitute 69% of overall revenues—both enjoy high ROCEs and high operating margins,” Chopra added. “We are confident of charting superior growth and delivering improved profitability in the medium to longer term.”